The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
about
AMD3100/CXCR4 InhibitorStructural Analysis of Chemokine Receptor-Ligand Interactions.Small molecule inhibitors of CXCR4.Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Targeting the protein-protein interactions of the HIV lifecycle.Development of novel CXCR4-based therapeutics.Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?Progress toward rationally designed small-molecule peptide and peptidomimetic CXCR4 antagonists.Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.A systematic approach to prioritize drug targets using machine learning, a molecular descriptor-based classification model, and high-throughput screening of plant derived molecules: a case study in oral cancer.Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology.Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
P2860
Q28087445-1318E86C-9C4D-44D8-8FF5-A223C341D308Q34550666-B92A06E2-531B-478B-A22C-A6E4561FDC8FQ34574987-90D887E2-632F-49BF-8C7B-4D15E6C73B70Q35213463-D140C797-B7CA-4A66-8662-C283F2B5F8BBQ36016645-3A83F70C-93B4-450B-8AB8-CBFE5E0F6BE9Q36191170-2810D894-F632-4BAB-B364-47C77BB88E57Q36334083-02553999-F56F-4384-BEA3-076E448B0803Q36445393-B0E7BB5D-9A17-4F0C-87B9-38F776BEF377Q37099769-84EB7BC0-B5AC-4D65-8272-C5ADAE1EF053Q37772888-5AC2A14E-4966-4BFE-80DE-F89BB0E72BB5Q37820252-82F60325-B43C-4F09-8B33-061CC524EDB1Q37979306-97FE8714-45B8-47CF-B5F6-A0B8702C9864Q37983913-08B14653-ED3F-4849-A7BD-F590D13A4340Q38542935-C9C6E18A-1C92-4119-BDA3-66E16D24BA94Q38808628-1D4E0B12-0576-4362-83CC-54D3CE5F5141Q38827863-A4F14DBE-9FE6-44D4-82A8-B069F3818044Q39104422-D128780B-09D2-4276-BBBD-A256F8C043F3Q40109819-FDECDC63-E6EE-4326-ADB8-628374E99E65Q47850217-2AF9452D-268F-4592-BD11-579704A72016
P2860
The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@en
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@nl
type
label
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@en
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@nl
prefLabel
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@en
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@nl
P2093
P2860
P356
P1476
The novel CXCR4 antagonist KRH ...... parative studies with AMD3100.
@en
P2093
Jun Komano
Kazu Okuma
Makiko Hamatake
Mikiro Yanaka
Reiko Tanaka
Sei Kumakura
Toru Yamazaki
Tsutomu Murakami
Yuetsu Tanaka
P2860
P304
P356
10.1128/AAC.01727-08
P407
P577
2009-05-18T00:00:00Z